Primary HASMC were obtained from Innoprot (Derio, Spain) and cultured as described.10 (link) Confluent cells were treated with medium supplemented with 20% of control or uremic human serum for the indicated period of time. When applicable, the Kv1.3-specific inhibitors 5-(4-phenoxybutoxy) psoralen (PAP-1, Sigma-Aldrich) and margatoxin (MgTx) were used at 100 nM22 (link),23 (link) and 10 nM,24 (link) respectively. All experiments were performed using cells between Passages 3 and 5.